GENFLOW BIOSCIENCES ORD GBP0.0003 overview

LONDON, UK / ACCESSWIRE / April 10, 2024 / TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BP2C3V08 Issuer Name GENFLOW BIOSCIENCES PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Premier Miton Group plc City of registered office (if applicable) GUILDFORD Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Full...

LONDON, UK / ACCESSWIRE / April 9, 2024 / Genflow Biosciences PLC (LSE:GENF)(OTCQB:GENFF) TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BP2C3V08 Issuer Name GENFLOW BIOSCIENCES PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name MR ERIC LEIRE City of registered office (if applicable) 15 Ingestre Place, Country of registered office (if applicable) UK...

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Announces Publication of a Key European Patent in Partnership with University of...

LONDON, UK / ACCESSWIRE / March 21, 2024 / TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BP2C3V08 Issuer Name GENFLOW BIOSCIENCES PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Jonathan Mark Swann City of registered office (if applicable) rickmansworth Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Full...

LONDON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (Genflow or the "Company”) (LSE:GENF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process is pleased to provide a year-end review and summary of its progress during 2023 and defined strategic priorities for 2024. The Company achieved many significant accomplishments throughout the year across all aspects of its business. The year-end review...

Secures Two Research Grants from Belgium's New Technological Innovation Partnership LONDON, UK / ACCESSWIRE / January 18, 2024 / The Company (LSE:GENF)(OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process is pleased to announce two significant new research programs in collaboration with Revatis SA and EXO Biologics, backed by substantial non-diluting and non-reimbursable research grants by the Government of...

LONDON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (Genflow or the "Company”) (LSE:GNF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process, in collaboration with Revatis SA and EXO Biologics, is proud to announce the initiation of two significant research programs backed by substantial non-diluting and non-reimbursable research grants by the Government of Wallonia in Belgium. Both of these...

Successful first regulatory interaction with the Federal Agency for Medicines and Health Products (FAHMP) And Internal Debt Restructuring First regulatory agency interaction results in recommendation to commence Phase I/II Clinical Trial in NASH Patients LONDON, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (“Genflow” or “the Company”) (LSE:GENF) (OTCQB:GENFF), today announced the receipt of written comments from the Federal Agency for Medicines and Health Products (FAHMP)...